-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$24.5080.15% Upside
Neumora Therapeutics, Inc. Common Stock Frequently Asked Questions
-
What analysts cover Neumora Therapeutics, Inc. Common Stock?
Neumora Therapeutics, Inc. Common Stock has been rated by research analysts at Needham, Mizuho Securities, RBC Capital, Stifel Nicolaus in the past 90 days.